Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study

Published:October 19, 2017DOI:



      We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab.

      Patients and Methods

      We assessed OS, progression-free survival (PFS), duration of disease control (DDC), the sum of the periods in which the disease did not progress, and the time to failure of strategy (TFS), which was defined as the entire period before the introduction of a second-line treatment. Linear correlation and regression models were used, and Prentice criteria were investigated.


      With a median follow-up of 57.6 months for 216 patients, the median OS was 24.5 months (95% confidence interval [CI], 21.3-29.7). The median PFS, DDC, and TFS were 8.9 (95% CI, 8.4-9.7), 11.0 (95% CI, 9.8-12.4), and 11.1 (95% CI, 10.0-13.0) months, respectively. The correlations between OS and DDC (Pearson coefficient, 0.79 [95% CI, 0.73-0.83], determination coefficient, 0.62) and OS and TFS (Pearson coefficient, 0.79 [95% CI, 0.73-0.84], determination coefficient, 0.63) were satisfactory. Linear regression analysis showed a significant association between OS and DDC, and between OS and TFS. Prentice criteria were verified for TFS as well as DDC.


      DDC and TFS correlated with OS and are relevant as intermediate criteria in the setting of patients with mCRC treated with a first-line bevacizumab-based regimen.


      To read this article in full you will need to make a payment


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hurwitz H.
        • Fehrenbacher L.
        • Novotny W.
        • et al.
        Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
        N Engl J Med. 2004; 350: 2335-2342
        • Van Cutsem E.
        • Cervantes A.
        • Adam R.
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 1386-1422
        • Chibaudel B.
        • Maindrault-Goebel F.
        • Lledo G.
        • et al.
        Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
        J Clin Oncol. 2009; 27: 5727-5733
        • Wasan H.
        • Meade A.M.
        • Adams R.
        • et al.
        Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 631-639
        • Simkens L.H.
        • van Tinteren H.
        • May A.
        • et al.
        Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
        Lancet. 2015; 385: 1843-1852
        • Hegewisch-Becker S.
        • Graeven U.
        • Lerchenmüller C.A.
        • et al.
        Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
        Lancet Oncol. 2015; 16: 1355-1369
        • Tournigand C.
        • Chibaudel B.
        • Samson B.
        • et al.
        Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2015; 16: 1493-1505
        • Johnsson A.
        • Hagman H.
        • Frodin J.E.
        • et al.
        A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
        Ann Oncol. 2013; 24: 2335-2341
        • Koeberle D.
        • Betticher D.C.
        • von Moos R.
        • et al.
        Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
        Ann Oncol. 2015; 26: 709-714
        • Stein A.
        • Schwenke C.
        • Folprecht G.
        • Arnold D.
        Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis.
        Clin Colorectal Cancer. 2016; 15: e29-e39
        • Tournigand C.
        • André T.
        • Achille E.
        • et al.
        FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
        J Clin Oncol. 2004; 22: 229-237
        • Tournigand C.
        • Cervantes A.
        • Figer A.
        • et al.
        OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer–a GERCOR study.
        J Clin Oncol. 2006; 24: 394-400
        • Chibaudel B.
        • Bonnetain F.
        • Shi Q.
        • et al.
        Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy–an Aide et Recherche en Cancerologie Digestive Group Study.
        J Clin Oncol. 2011; 29: 4199-4204
        • Shi Q.
        • de Gramont A.
        • Grothey A.
        • et al.
        Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the Analysis and Research in Cancers of the Digestive System Database.
        J Clin Oncol. 2015; 33: 22-28
        • Aprile G.
        • Giuliani F.
        • Lutrino S.E.
        • et al.
        Maintenance therapy in colorectal cancer: moving the artillery down while keeping an eye on the enemy.
        Clin Colorectal Cancer. 2016; 15: 7-15
        • Prentice R.L.
        Surrogate end points in clinical trials: definition and operational criteria.
        Stat Med. 1989; 8: 431-440
        • Kramar A.
        • Mathoulin-Pélissier S.
        Méthodes biostatistiques appliquées à la recherche clinique en cancérologie [Biostatistical methods applied to clinical research in oncology].
        ([in French]) John Libbey Eurotext, Montrouge, France2011
        • Tamburini E.
        • Rudnas B.
        • Santelmo C.
        • et al.
        Maintenance-based bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: a meta-analysis of randomized clinical trials.
        Crit Rev Oncol Hematol. 2016; 104: 115-123
        • Quidde J.
        • Hegewisch-Becker S.
        • Graeven U.
        • et al.
        Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
        Ann Oncol. 2016; 27: 2203-2210
        • Chibaudel B.
        • Bonnetain F.
        • Tournigand C.
        • de Gramont A.
        Maintenance treatment in metastatic colorectal cancer.
        Lancet Oncol. 2015; 16: e583-e584
        • Heinemann V.
        • von Weikersthal L.F.
        • Decker T.
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 1065-1075
        • Heinemann V.
        • Stintzing S.
        FOLFIRI with cetuximab or bevacizumab: FIRE-3–authors' reply.
        Lancet Oncol. 2014; 15: e583-e584
        • Cappuzzo F.
        • Ciuleanu T.
        • Stelmakh L.
        • et al.
        Erlotinib as maintenance treatment in advanced non–small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
        Lancet Oncol. 2010; 11: 521-529
        • Barlesi F.
        • Scherpereel A.
        • Rittmeyer A.
        • et al.
        Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
        J Clin Oncol. 2013; 31: 3004-3011
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N Engl J Med. 2011; 365: 2473-2483
        • Perren T.J.
        • Swart A.M.
        • Pfisterer J.
        • et al.
        A phase 3 trial of bevacizumab in ovarian cancer.
        N Engl J Med. 2011; 365: 2484-2496
        • Chibaudel B.
        • Bonnetain F.
        • Tournigand C.
        • et al.
        STRATEGIC-1: a multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
        BMC Cancer. 2015; 15: 496
        • Kaplan R.
        • Maughan T.
        • Crook A.
        • et al.
        Evaluating many treatments and biomarkers in oncology: a new design.
        J Clin Oncol. 2013; 31: 4562-4568
        • Schmoll H.
        • Arnold D.
        • de Gramont A.
        • et al.
        MODUL–a multicentre randomised clinical trial of biomarker-driven therapy for the 1st-line maintenance treatment of metastatic colorectal cancer (mCRC): a signal-seeking approach.
        Ann Oncol. 2014; 25: iv209
        • Cremolini C.
        • Loupakis F.
        • Antoniotti C.
        • et al.
        Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
        Ann Oncol. 2015; 26: 1188-1194
        • Buyse M.
        • Sargent D.J.
        • Goldberg R.M.
        • de Gramont A.
        • ARCAD Clinical Trials Program
        The ARCAD advanced colorectal cancer database–open for business.
        Ann Oncol. 2012; 23: 281-282